guide

(redirected from Guidant)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
A global leader in the medical technology industry, Guidant Corporation provides innovative, minimally invasive and cost-effective products and services for the treatment of cardiovascular and vascular disease.
The action in Ireland is one of four patent infringement actions against Guidant products involving the evYsio patents.
Guidant is ramping up manufacturing and building inventory to supply ongoing clinical trials and to support the European launch of XIENCE V beginning in the second quarter of 2006.
Guidant will work with Dartmouth Medical School and the Centers for Medicare and Medicaid Services (CMS) to potentially link to the Medicare database to collect one-year patient outcomes.
com/cases/guidantcorp/) today announced that class actions have been commenced in the United States District Court for the Southern District of Indiana on behalf of purchasers of Guidant Corporation ("Guidant") (NYSE:GDT) publicly traded securities during the period between December 15, 2004 and November 4, 2005 (the "Class Period").
Since Guidant introduced bipolar left ventricular leads in Europe in 2002, physicians have rapidly and overwhelmingly adopted this technology.
In connection with the proposed merger between Guidant Corporation and Johnson & Johnson, Guidant and Johnson & Johnson will file with the SEC a post-effective amendment to their prospectus/proxy statement.
NOTE TO MEDIA: For more information about Guidant, including products, services and patient profiles, please visit the company's newsroom at www.
Guidant Corporation and Johnson & Johnson have filed with the Securities and Exchange Commission (SEC) a definitive proxy statement/prospectus and other documents regarding the proposed merger between Guidant and Johnson & Johnson.
Rather than granting or denying the lead derivative plaintiff's request for a Temporary Restraining Order ("TRO") to enjoin several provisions in the November 14, 2005 merger agreement between Guidant Corp.
INDIANAPOLIS -- Guidant Corporation (NYSE:GDT) acknowledges receipt today, January 8, 2006, of a definitive offer from Boston Scientific Corporation to acquire Guidant for $72 per Guidant share made up of a combination of half cash and half stock.